BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 27986747)

  • 1. Histone Deacetylase 3 Inhibition Overcomes
    Tanimoto A; Takeuchi S; Arai S; Fukuda K; Yamada T; Roca X; Ong ST; Yano S
    Clin Cancer Res; 2017 Jun; 23(12):3139-3149. PubMed ID: 27986747
    [No Abstract]   [Full Text] [Related]  

  • 2. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
    Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
    Takeuchi S; Hase T; Shimizu S; Ando M; Hata A; Murakami H; Kawakami T; Nagase K; Yoshimura K; Fujiwara T; Tanimoto A; Nishiyama A; Arai S; Fukuda K; Katakami N; Takahashi T; Hasegawa Y; Ko TK; Ong ST; Yano S
    Cancer Sci; 2020 Feb; 111(2):561-570. PubMed ID: 31782583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.
    Arai S; Takeuchi S; Fukuda K; Tanimoto A; Nishiyama A; Konishi H; Takagi A; Takahashi H; Ong ST; Yano S
    J Med Invest; 2020; 67(3.4):343-350. PubMed ID: 33148913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.
    Takeuchi S; Yoshimura K; Fujiwara T; Ando M; Shimizu S; Nagase K; Hasegawa Y; Takahashi T; Katakami N; Inoue A; Yano S
    J Med Invest; 2017; 64(3.4):321-325. PubMed ID: 28955007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
    Shi P; Oh YT; Deng L; Zhang G; Qian G; Zhang S; Ren H; Wu G; Legendre B; Anderson E; Ramalingam SS; Owonikoko TK; Chen M; Sun SY
    Clin Cancer Res; 2017 Nov; 23(21):6567-6579. PubMed ID: 28765329
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
    Li X; Zhang D; Li B; Zou B; Wang S; Fan B; Li W; Yu J; Wang L
    Lung Cancer; 2021 Jan; 151():39-43. PubMed ID: 33296806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
    Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review.
    Li X; Wang S; Li B; Wang Z; Shang S; Shao Y; Sun X; Wang L
    Target Oncol; 2018 Aug; 13(4):517-523. PubMed ID: 29907952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
    Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
    Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
    Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY
    Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
    Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction.
    Han R; Hao S; Lu C; Zhang C; Lin C; Li L; Wang Y; Hu C; He Y
    Mol Oncol; 2020 Jun; 14(6):1152-1169. PubMed ID: 32239624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
    Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
    J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
    Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
    BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.
    Lu Y; Bian D; Zhang X; Zhang H; Zhu Z
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
    Ariyasu R; Yanagitani N; Tadokoro K; Yamaguchi T; Uchibori K; Kitazono S; Fujita N; Katayama R; Nishio M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):517-525. PubMed ID: 32948919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.